HK Stock MarketDetailed Quotes

02126 JW THERAP-B

Watchlist
  • 1.750
  • +0.030+1.74%
Not Open Apr 25 16:09 CST
725.13MMarket Cap-855P/E (TTM)

About JW THERAP-B Company

Pharmaceutical Ming Junuo (Hong Kong Stock Exchange Code: 2126) is an independent and innovative biotechnology company that focuses on developing, producing and commercializing cellular immunotherapy products, and is committed to leading innovation to become a leader in cellular immunotherapy. Established in 2016, Pharmaceutical MingJunuo has successfully built the world's leading comprehensive product development platform for cellular immunotherapy, as well as a cellular immunotherapy product pipeline covering hematologic tumors, solid tumors, and autoimmune diseases. Pharmaceutical Ming Junuo is committed to bringing hope for healing to patients in China and the world with breakthrough, high-quality cellular immunotherapy products, and leading the development of health standards in China's cellular immunotherapy industry.

Company Profile

Symbol02126
Company NameJW THERAP-B
ISINKYG5210T1040
Listing DateNov 3, 2020
Issue Price23.80
Shares Offered97.69M share(s)
FoundedSep 6, 2017
Registered AddressCayman Islands
Chairmanyiping li
Secretaryjiawen wu
Audit InstitutionPricewaterhouseCoopers
Company CategoryOther
Registered OfficeMaples Corporate Services Limited Office PO Box 309, Ugland House Grand Cayman, KY1-1104 Cayman Islands
Head Office and Principal Place of Business31st Floor, Tower 2, Times Square, 1 Matheson Street, Causeway Bay, Hong Kong
Fiscal Year Ends12-31
Employees398
MarketHong Kong motherboard
Phone(86)2150783699
Websitehttp://www.jwtherapeutics.com/
Business Pharmaceutical Mingjuunuo (Cayman) Co., Ltd. is a Chinese company mainly engaged in clinical and pre-clinical cell therapy. The company is committed to developing cell therapies for the Chinese market and bringing new treatments to cancer patients in China. Through its subsidiary, it has established an integrated platform focused on developing, manufacturing and commercializing breakthrough cellular immunotherapy treatments for hematologic cancers and solid tumors. Its main candidate product, relmacabtagene autoleucel (relma-cel), is an autologous anti-CD19 CAR-T therapy for recurrent or refractory (r/r) B-cell lymphoma. The company mainly operates in the Chinese market.

Company Executives

  • Name
  • Position
  • Salary
  • yiping li
  • CEOs，presidencies，Executive Director，Chairman of the Nomination Committee，Strategy Committee Member，Authorized Representative
  • --
  • xing gao
  • Non-executive directors，Audit Committee Members
  • --
  • Sungwon Song
  • Non-executive directors，Remuneration Committee Members
  • --
  • cheng liu
  • Non-executive directors
  • --
  • yaoliang zhang
  • Independent Non-Executive Director，Chairman of the Audit Committee，Nomination Committee Members
  • --
  • jianchang he
  • Independent Non-Executive Director，Remuneration Committee Members，Audit Committee Members
  • --
  • jiuyun yu
  • Independent Non-Executive Director，Co-Chairman of the Strategy Committee，Nomination Committee Members，Remuneration Committee Members
  • --
  • Krishnan Viswanadhan
  • Independent Non-Executive Director，Co-Chairman of the Strategy Committee，Nomination Committee Members
  • --
  • Ann Li Lee
  • Independent Non-Executive Director，Remuneration Committee Chairman
  • --
  • xin fu
  • senior vice president
  • --
  • qiong wu
  • Chief Commercial Officer
  • --
  • Shaun Paul Cordoba
  • senior vice president，Chief Scientific Officer
  • --
  • su yang
  • Executive Director of Clinical Research and Development
  • --
  • Raymond J. Hage, Jr.
  • senior vice president
  • --
  • jiawen wu
  • Company Secretary，Authorized Representative
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
%Chg